ResMed RMD Sleep And Breathing Health — R&D
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ResMed in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: ResMed’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about ResMed's sleep and breathing health — r&d.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ResMed's sleep and breathing health — R&D?
- ResMed (RMD) reported sleep and breathing health — R&D of $56.41M in Q1 2026.
- How has ResMed's sleep and breathing health — R&D changed year-over-year?
- ResMed's sleep and breathing health — R&D increased by 19.4% year-over-year, from $47.24M to $56.41M.
- What is the long-term trend for ResMed's sleep and breathing health — R&D?
- Over 2 years (2023 to 2025), ResMed's sleep and breathing health — R&D has grown at a 5.8% compound annual growth rate (CAGR), from $175.39M to $196.34M.
- What does sleep and breathing health — R&D mean?
- Refers to the expenditures dedicated to innovation, product design, and clinical trials specifically for the Sleep and Breathing Health segment. This investment is critical for maintaining a competitive edge in respiratory care and developing next-generation therapy devices. It reflects the company's commitment to long-term product pipeline growth.